Emedgene
- Company typePrivate
- Founded2015
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Emedgene firmographics
Firmographics- Name
- Emedgene
- Website
- https://emedgene.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Emedgene industry classification
Industry- Product category
- Genomic Informatics Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Emedgene is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Emedgene business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software Licensing/Subscription: Emedgene is sold as part of Illumina's informatics product portfolio. The product is offered via enterprise sales with 'Request a demo' pricing, indicating a subscription or perpetual license model typical of enterprise software. Pricing is not publicly disclosed and requires direct consultation with Illumina sales team.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise pricing - quote-based |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Emedgene product offering
Product offeringCore offering
Emedgene provides a germline variant interpretation software platform that uses explainable AI to prioritize variants and automate ACMG classifications across WGS, WES, virtual panels, targeted panels, and microarray data. The platform exposes API interoperability that links tertiary analysis with laboratory information management systems and integrates natively with Illumina DRAGEN secondary analysis, enabling clinical genetics laboratories and research institutions to scale interpretation throughput while reducing manual review time.
Product overview
Emedgene is a unified software platform for germline variant interpretation that combines AI-powered analysis with workflow automation. The core Emedgene Software platform supports whole-genome sequencing (WGS), whole-exome sequencing (WES), virtual panels, targeted panels, and microarrays. It integrates with Illumina DRAGEN secondary analysis and offers API interoperability for connecting with laboratory information management systems. The platform features explainable AI for variant prioritization, automated ACMG classifications, and collaborative knowledge sharing across private lab networks.
Differentiator
Problem solved
Functional benefit
Products and services
- Emedgene Software Unified software platform for germline variant interpretation and tertiary analysis, using explainable AI to prioritize variants and automate ACMG classifications across WGS, WES, virtual panels, targeted panels, and microarrays. Built for clinical genetic laboratories and research institutions and integrated with Illumina DRAGEN secondary analysis and LIMS systems via API.
Quantifiable outcome
- 97% accuracy in prioritizing relevant insights
- +2 more outcomes
Companies that use Emedgene
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Emedgene technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature6 records
Emedgene partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Illumina (Parent Company)coreEmedgene was acquired by Illumina and is now marketed and sold as an Illumina product under the informatics product portfolio. The software integrates natively with other Illumina products including DRAGEN secondary analysis and Illumina Connected Analytics platforms.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Emedgene competitors and assessment
Company assessmentDirect peers
- Sophia Genetics: Sophia Genetics offers AI-driven genomic and multimodal data analysis for clinical genomics, including variant interpretation for hereditary disease and oncology — directly overlapping Emedgene's clinical variant interpretation focus.
- Congenica: Congenica provides clinical genomics interpretation software for rare disease and inherited disorders, competing head-to-head with Emedgene in tertiary analysis and ACMG-classified variant reporting for clinical labs.
- Fabric Genomics (now Velsera): Fabric Genomics delivers AI-powered genomic interpretation for hereditary disease and rare disease workflows, offering a comparable tertiary analysis platform to Emedgene's clinical genetics focus.
- BC Platforms: BC Platforms offers genomic data management and clinical interpretation tools for hospitals and research institutions, providing an alternative tertiary analysis platform to Emedgene's clinical genomics workflows.
- PierianDx: PierianDx provides clinical genomics software for variant interpretation and clinical reporting, targeting hospital and health system labs with workflows overlapping Emedgene's clinical genetic laboratory use case.
Emerging players
- Genomenon: Genomenon provides AI-driven genomic literature curation and variant intelligence used in clinical interpretation pipelines, addressing the same evidence-back variant prioritization problem Emedgene solves with XAI.
- Variantyx: Variantyx offers AI-enabled clinical genomic testing and interpretation services for rare disease diagnostics, intersecting with Emedgene's clinical lab and tertiary analysis use cases from a service-provider angle.
Broad incumbents
- DNAnexus: DNAnexus provides a cloud-based genomics data analysis and management platform used by clinical and research institutions; its pipelines can support variant interpretation workflows comparable to Emedgene's tertiary analysis.
- Illumina Connected Insights: Illumina Connected Insights is Illumina's own somatic variant interpretation platform; as a sibling product in the same Illumina informatics portfolio, it directly competes for interpretation workloads alongside Emedgene.
- QIAGEN Digital Insights (QCI): QIAGEN Digital Insights offers a broad bioinformatics and variant interpretation suite (including QCI Interpret) for clinical and research genomics, competing with Emedgene from a larger established life sciences tools platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Emedgene social profiles
Digital presenceEmedgene compliance and trust
Trust signalCompliance1 record
Emedgene financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emedgene leadership team
Management profileNumber of profiles
Profiles2 records
Emedgene funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emedgene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emedgene
What does Emedgene do?
Emedgene provides a germline variant interpretation software platform that uses explainable AI to prioritize variants and automate ACMG classifications across WGS, WES, virtual panels, targeted panels, and microarray data. The platform exposes API interoperability that links tertiary analysis with laboratory information management systems and integrates natively with Illumina DRAGEN secondary analysis, enabling clinical genetics laboratories and research institutions to scale interpretation throughput while reducing manual review time.
Is Emedgene a public or private company?
Emedgene is a private company. It is classified as corporate owned and is currently operating.
When was Emedgene founded?
Emedgene was founded in 2015. It employs 11 to 50 people.
Where is Emedgene based?
Emedgene is headquartered in Palo Alto, United States, in the North America region.
How does Emedgene make money?
One revenue line is on record: software Licensing/Subscription.
Who are Emedgene's main competitors?
Direct peers on record are Sophia Genetics, Congenica, Fabric Genomics (now Velsera), BC Platforms and PierianDx. Emerging players are Genomenon and Variantyx. Broad incumbents are DNAnexus, Illumina Connected Insights and QIAGEN Digital Insights (QCI).
Does Emedgene have an API?
Yes. Emedgene offers API interoperability enabling integration with laboratory information management systems, storage, pipelines, and other workflows. The API supports linking tertiary analysis with various systems for streamlined data operations.
What industry is Emedgene in?
Emedgene's product category is Genomic Informatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 5132 and its SIC code is 7372.